These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2788420)

  • 21. Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
    Gangjee A; Shi J; Queener SF
    J Med Chem; 1997 Jun; 40(12):1930-6. PubMed ID: 9191971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
    Gangjee A; Elzein E; Queener SF; McGuire JJ
    J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1995 May; 38(10):1778-85. PubMed ID: 7752201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
    Chan DC; Laughton CA; Queener SF; Stevens MF
    J Med Chem; 2001 Aug; 44(16):2555-64. PubMed ID: 11472209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Mavandadi F; Queener SF
    J Med Chem; 1997 Mar; 40(7):1173-7. PubMed ID: 9089339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
    Matherly LH; Barlowe CK; Goldman ID
    Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Hynes JB; Queener SF
    Antimicrob Agents Chemother; 1995 Jan; 39(1):79-86. PubMed ID: 7695334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Pneumocystis dihydrofolate reductase by analogs of pyrimethamine, methotrexate and trimetrexate.
    Queener SF
    J Protozool; 1991; 38(6):154S-157S. PubMed ID: 1840146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Papoulis AT; Queener SF
    J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates.
    Fry DW; Besserer JA
    Cancer Res; 1988 Dec; 48(24 Pt 1):6986-91. PubMed ID: 2973370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.
    Broughton MC; Queener SF
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1348-55. PubMed ID: 1929292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
    Shah K; Queener S; Cody V; Pace J; Gangjee A
    Bioorg Med Chem Lett; 2019 Aug; 29(15):1874-1880. PubMed ID: 31176699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
    Nelson RG; Rosowsky A
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3293-303. PubMed ID: 11709300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.